A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma.

ABSTRACT:

Background

Effective maintenance therapy for urothelial carcinoma (UC) is needed to delay progression after first-line chemotherapy.

Objective

To evaluate S-588410, a cancer peptide vaccine containing five human leukocyte antigen (HLA)-A^*24:02-restricted epitope peptides derived from five cancer-testis antigens (DEPDC1, MPHOSPH1, URLC10, CDCA1, and KOC1) in chemotherapy-treated, clinically stable patients with advanced or metastatic UC.

Materials and methods

This open-label, international, phase 2 trial enrolled patients with UC who had completed≥4 cycles of first-line platinum-containing chemotherapy without disease progression. Forty-five HLA-A^*24:02-positive patients received subcutaneous injections of S-588410 (Montanide ISA 51 VG with 1 mg/m

SUBMITTER: Shimizu N 

PROVIDER: S-EPMC11181746 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature